Dianthus Therapeutics (DNTH) Competitors $19.62 -1.98 (-9.17%) Closing price 04:00 PM EasternExtended Trading$19.70 +0.08 (+0.41%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DNTH vs. BEAM, CPRX, TWST, MIRM, ARWR, EWTX, GMTX, KYMR, IBRX, and PTGXShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Beam Therapeutics (BEAM), Catalyst Pharmaceuticals (CPRX), Twist Bioscience (TWST), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), Edgewise Therapeutics (EWTX), Gemini Therapeutics (GMTX), Kymera Therapeutics (KYMR), ImmunityBio (IBRX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Beam Therapeutics Catalyst Pharmaceuticals Twist Bioscience Mirum Pharmaceuticals Arrowhead Pharmaceuticals Edgewise Therapeutics Gemini Therapeutics Kymera Therapeutics ImmunityBio Protagonist Therapeutics Beam Therapeutics (NASDAQ:BEAM) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Is BEAM or DNTH more profitable? Beam Therapeutics has a net margin of -41.07% compared to Dianthus Therapeutics' net margin of -1,250.32%. Beam Therapeutics' return on equity of -16.22% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-41.07% -16.22% -10.94% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Do insiders & institutionals believe in BEAM or DNTH? 99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 4.2% of Beam Therapeutics shares are owned by company insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings & valuation, BEAM or DNTH? Dianthus Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M33.07-$132.53M-$4.58-5.48Dianthus Therapeutics$5.37M108.22-$43.56M-$2.50-7.85 Does the MarketBeat Community believe in BEAM or DNTH? Beam Therapeutics received 36 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 95.83% of users gave Dianthus Therapeutics an outperform vote while only 56.19% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformBeam TherapeuticsOutperform Votes5956.19% Underperform Votes4643.81% Dianthus TherapeuticsOutperform Votes2395.83% Underperform Votes14.17% Which has more volatility & risk, BEAM or DNTH? Beam Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Does the media refer more to BEAM or DNTH? In the previous week, Beam Therapeutics had 38 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 41 mentions for Beam Therapeutics and 3 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.62 beat Beam Therapeutics' score of 0.39 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 5 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate BEAM or DNTH? Beam Therapeutics currently has a consensus price target of $51.00, suggesting a potential upside of 103.19%. Dianthus Therapeutics has a consensus price target of $46.83, suggesting a potential upside of 138.70%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 SummaryBeam Therapeutics and Dianthus Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$580.69M$7.21B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-7.856.1524.9519.21Price / Sales108.22187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book1.726.447.334.28Net Income-$43.56M$139.03M$3.18B$247.04M7 Day Performance-9.17%-5.52%-4.42%-4.36%1 Month Performance-11.10%-8.56%-6.07%-5.60%1 Year Performance-23.81%-14.59%11.42%3.38% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.868 of 5 stars$19.62-9.2%$46.83+138.7%-16.1%$580.69M$5.37M-7.8580BEAMBeam Therapeutics3.6921 of 5 stars$30.79+1.2%$47.67+54.8%-33.9%$2.55B$377.71M-17.49510Earnings ReportAnalyst ForecastAnalyst RevisionCPRXCatalyst Pharmaceuticals4.9165 of 5 stars$21.25-1.7%$32.25+51.8%+34.6%$2.53B$460.48M18.0180Analyst ForecastNews CoverageTWSTTwist Bioscience4.3132 of 5 stars$41.20-0.3%$54.40+32.0%-0.2%$2.46B$312.97M-12.19990Positive NewsMIRMMirum Pharmaceuticals3.9355 of 5 stars$50.95-2.9%$57.10+12.1%+62.5%$2.45B$186.37M-25.22140Earnings ReportAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.7537 of 5 stars$18.86-5.2%$41.44+119.7%-47.6%$2.38B$2.50M-3.65400EWTXEdgewise Therapeutics2.125 of 5 stars$25.01-7.6%$41.29+65.1%+56.8%$2.37BN/A-16.6760Earnings ReportNews CoveragePositive NewsGMTXGemini TherapeuticsN/A$54.53+0.3%N/A-25.4%$2.36BN/A-54.5330High Trading VolumeKYMRKymera Therapeutics2.16 of 5 stars$35.31-4.1%$55.64+57.6%-27.9%$2.29B$78.59M-15.09170Earnings ReportAnalyst ForecastAnalyst RevisionIBRXImmunityBio2.1187 of 5 stars$3.22-5.8%$13.58+321.8%-30.1%$2.24B$620,000.00-3.50590Earnings ReportAnalyst ForecastNews CoverageGap DownPTGXProtagonist Therapeutics3.7472 of 5 stars$36.00-7.1%$55.44+54.0%+16.9%$2.15B$323.80M13.53120Analyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies Beam Therapeutics Alternatives Catalyst Pharmaceuticals Alternatives Twist Bioscience Alternatives Mirum Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Gemini Therapeutics Alternatives Kymera Therapeutics Alternatives ImmunityBio Alternatives Protagonist Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DNTH) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts